a16z Bio + Health

MODERATE Tx Startup

Strategy Notes

Strong thematic alignment: a16z Bio explicitly invests in AI-driven drug discovery at the technology/biology convergence, directly matching the venture's focus. However, significant mismatches on stage (pre-seed vs seed minimum), funding type (non-dilutive preferred vs equity VC), and geography (EU vs US-based). Better suited once incorporated at seed stage.

Key Materials

—

Your Notes

Status & Deadline

Status: INELIGIBLE
Deadline: rolling
Cycle: rolling
Amount: —
Type: vc
URL: Apply

Update Status

Log Application

AI Pipeline

Research Programme Generate Draft

Status History

2026-07-09 OPEN → INELIGIBLE · Three compounding hard blockers: (1) applicant is not yet incorporated — a16z requires a legal entity to invest in; (2) pre-seed stage falls below a16z's effective seed minimum for check deployment; (3) fund is US-primary with no stated EU mandate, and the applicant is targeting Île-de-France incorporation.